| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -17,633 | -20,538 |
| Stock-based compensation | 52,398 | 34,271 |
| Depreciation and amortization | 18,170 | 12,108 |
| Inventory reserves and firm commitment losses | -2,889 | -2,349 |
| Amortization of debt discount and offering costs | 1,303 | 860 |
| Unrealized foreign exchange gain | 1,913 | 1,270 |
| Non-cash lease expense | 1,273 | 826 |
| Other | 1,019 | 674 |
| Accounts receivable | 29,047 | 25,901 |
| Prepaid and other current assets | 11,746 | 7,114 |
| Inventory | 6,166 | 5,007 |
| Other assets | 4,026 | 1,342 |
| Accounts payable, accrued expenses and other liabilities | 46,660 | 22,314 |
| Operating lease liabilities | -1,383 | -803 |
| Net cash provided by operating activities | 49,760 | 10,079 |
| Purchase of investments | 85,923 | 65,063 |
| Proceeds from maturities of investments | 61,317 | 42,497 |
| Purchase of property and equipment | 354 | 167 |
| Payments made for additions to intangible assets | 0 | 0 |
| Net cash used in investing activities | -24,960 | -22,733 |
| Proceeds from issuance of common stock pursuant to equity plans | 31,143 | 15,047 |
| Net cash provided by financing activities | 31,143 | 15,047 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | 3,630 | 3,281 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 59,573 | 5,674 |
| Cash and cash equivalents at beginning of period | 222,928 | - |
| Cash and cash equivalents at end of period | 282,501 | - |
Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM)